Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide vs placebo in non-metastatic castration-resistant prostate cancer (Japanese Phase III)
jRCT2080223069Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in castration-resistant prostate cancer (CRPC) comparing Apalutamide arm with Placebo arm (2 arms). Started Jan 2016; status: completed.
02
Drugs
apalutamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on jRCT2080223069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223069.